Hepcinat Plus 60mg/400mg Tablet (Sofosbuvir 400mg + Daclatasvir 60mg)

Hepcinat Plus 60mg/400mg Tablet combines sofosbuvir 400 mg, an HCV NS5B polymerase inhibitor, with daclatasvir 60 mg, an NS5A inhibitor. This direct-acting antiviral combination has been widely used internationally for chronic hepatitis C, particularly in generic-access programs. However, daclatasvir is no longer marketed in some jurisdictions, and many current guidelines prefer pan-genotypic combinations such as sofosbuvir/velpatasvir or glecaprevir/pibrentasvir. Therefore, genotype, cirrhosis, prior treatment, and local guideline status must be confirmed before use.

Sofosbuvir 400 mg + Daclatasvir 60 mg tablets can treat chronic HCV across multiple genotypes, but duration and the need for ribavirin have historically varied by genotype, cirrhosis, and treatment history. In many settings, 12 weeks has been used for uncomplicated disease, while longer therapy or ribavirin was used for difficult-to-treat populations. Before therapy, HBV screening is required because reactivation can occur during DAA treatment. Current Indian/national guidance should determine whether SOF/DCV remains a preferred or alternative regimen for the patient’s genotype and disease stage.

Sofosbuvir 400mg is converted to a nucleotide analogue that terminates HCV RNA synthesis by NS5B. Daclatasvir 60mg tablet binds NS5A and disrupts viral RNA replication and virion assembly.

ALLY development program: Daclatasvir 60 mg-based combinations demonstrated high SVR rates across several HCV genotypes and difficult-to-treat populations.

Global generic program evidence: SOF/DCV has produced high real-world cure rates in national hepatitis-C elimination programs, though preferred regimens have evolved.

Just like any other medication, the Hepcinat Plus 60mg/400mg Tablet is also associated with some side effects. Most of the side effects are minor and usually go away within some time. Here are some of the symptoms, including:

Common side effects

• Headache
• Fatigue
• Nausea

Serious side effects

• HBV reactivation
• Serious bradycardia when the Sofosbuvir Plus Tablet is combined with amiodarone
• Treatment failure from strong enzyme-inducing interactions

Important: Dose and regimen must be prescribed by the treating specialist. Tablet/vial strength is not necessarily the patient dose. Do not start, stop, split, combine, or substitute treatment based on website information.

Take a missed dose when remembered unless close to the next dose; do not double. Repeated missed doses can reduce cure probability.

• HCV RNA response/SVR12
• HBV serology
• Liver fibrosis/cirrhosis status
• Drug-interaction review
• Adherence​
  

• Current national/WHO HCV treatment guidance for regimens that include daclatasvir. https://cdn.who.int/media/docs/default-source/maldives/national-hepatitis-c-guideline-2019.pdf​
• Current sofosbuvir prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204671s013lbl.pdf​
• ALLY programme studies of daclatasvir-based HCV therapy. https://pubmed.ncbi.nlm.nih.gov/25614962/​
• Current AASLD-IDSA/EASL guidance for present-day preferred-regimen context. https://www.aasld.org/practice-guidelines​
• National library of medicine. Sofosbuvir: A novel treatment option for chronic hepatitis c infection https://pmc.ncbi.nlm.nih.gov/articles/PMC4231565/​